How's my detailing? Dial 1-877-RX-DDMAC

Share this article:
How's my detailing? Dial 1-877-RX-DDMAC
How's my detailing? Dial 1-877-RX-DDMAC
The FDA is asking healthcare professionals to keep an eye out for violative promotion and to call 1-877-RX-DDMAC or emailing when they see it.

"Recognize and report" is the message of the agency's Bad Ad Program, an educational outreach effort by the Division of Drug Marketing, Advertising and Communications (DDMAC) that will “help healthcare providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency,” according to DDMAC director Tom Abrams.

The program will be rolled out in three phases, said FDA. In Phase 1, DDMAC will engage healthcare providers and distribute educational materials at select medical conventions and through partnerships with medical societies. Phases 2 and 3 “will expand the FDA's collaborative efforts and update the educational materials developed for Phase 1,” said FDA.

The program represents an effort to expand the agency's monitoring capability by enlisting the targets of promotion to serve as FDA's eyes and ears on the street. Traditionally, the agency noted, monitoring efforts have relied on reviews of promotional pieces submitted by drug companies, industry complaints and field surveillance at big medical conventions.

“Although these efforts are effective, the agency has limited ability to monitor promotional activities that occur in private,” said FDA.

Reports can be submitted anonymously, though the agency will encourage callers to leave contact info for follow-ups, the agency said. The website for the program is at:
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...